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Abstract
Background: Depressive symptoms are common in people with type 2 diabetes mellitus (T2DM). Effective depression treatments
exist; however, access to psychological support is characteristically low. Web-based cognitive behavioral therapy (CBT) is
accessible, nonstigmatizing, and may help address substantial personal and public health impact of comorbid T2DM and depression.
Objective: The aim of this study was to evaluate the Web-based CBT program, myCompass, for improving social and occupational
functioning in adults with T2DM and mild-to-moderate depressive symptoms. myCompass is a fully automated, self-guided
public health treatment program for common mental health problems. The impact of treatment on depressive symptoms,
diabetes-related distress, anxiety symptoms, and self-care behavior was also examined.
Methods: Participants with T2DM and mild-to-moderate depressive symptoms (N=780) were recruited online via Google and
Facebook advertisements targeting adults with T2DM and via community and general practice settings. Screening, consent, and
self-report scales were all self-administered online. Participants were randomized using double-blind computerized block
randomization to either myCompass (n=391) for 8 weeks plus a 4-week tailing-off period or an active placebo intervention
(n=379). At baseline and postintervention (3 months), participants completed the Work and Social Adjustment Scale, the primary
outcome measure. Secondary outcome measures included the Patient Health Questionnaire-9 item, Diabetes Distress Scale,
Generalized Anxiety Disorder Questionnaire-7 item, and items from the Self-Management Profile for Type 2 Diabetes.
Results: myCompass users logged in an average of 6 times and completed an average of .29 modules. Healthy Lifestyles users
logged in an average of 4 times and completed an average of 1.37 modules. At baseline, mean scores on several outcome measures,
including the primary outcome of work and social functioning, were near to the normal range, despite an extensive recruitment
process. Approximately 61.6% (473/780) of participants completed the postintervention assessment. Intention-to-treat analyses
revealed improvement in functioning, depression, anxiety, diabetes distress, and healthy eating over time in both groups. Except
for blood glucose monitoring and medication adherence, there were no specific between-group effects. Follow-up analyses
suggested the outcomes did not depend on age, morbidity, or treatment engagement.
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Conclusions: Improvement in social and occupational functioning and the secondary outcomes was generally no greater for
myCompass users than for users of the control program at 3 months postintervention. These findings should be interpreted in
light of near-normal mean baseline scores on several variables, the self-selected study sample, and sample attrition. Further
attention to factors influencing uptake and engagement with mental health treatments by people with T2DM, and the impact of
illness comorbidity on patient conceptualization and experience of mental health symptoms, is essential to reduce the burden of
T2DM.
Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12615000931572;
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368109&isReview=true (Archived by WebCite at
http://www.webcitation.org/7850eg8pi)
(J Med Internet Res 2019;21(5):e12246)  doi: 10.2196/12246
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Introduction
Background
Type 2 diabetes mellitus (T2DM) is a global public health
problem, affecting more than 370 million people worldwide
[1,2]. The disease is the fastest growing chronic condition in
Australia, with approximately 1 million people diagnosed and
up to 500,000 undiagnosed [3]. In addition to increased risk of
adverse health consequences (including macro and
microvascular diseases), people diagnosed with T2DM are at
greater risk of psychiatric and neurodegenerative disorders, as
well as physical disability and functional decline, than the
general population [4,5]. With the prediction that global
prevalence rates will increase to nearly 600 million by 2035
[3], T2DM presents a substantial escalating challenge for health
care delivery and public health infrastructure in Australia and
around the globe.
Depression is frequently comorbid with T2DM, affecting up to
40% of people with the disease [6,7]. Comorbid depression is
associated with greater disease morbidity, mortality, and health
care costs. These relationships are likely because of poor
occupational and social functioning, reduced regimen adherence,
poor quality of life, and increased need for outpatient and
inpatient health services in people with both disorders [6,8,9].
The interrelationship between T2DM and depressive symptoms
[10] further complicates the situation, with research showing
that each condition increases the negative functional and health
impacts of the other [6]. A population-based early intervention
program for depression in people with T2DM is urgently needed
to reduce both the substantial personal burden and public health
impact of these comorbid conditions.
International diabetes treatment guidelines now recommend
regular screening for depressive symptoms, with referral to
appropriate psychological treatments as part of standard diabetes
care [11]. Cognitive behavioral therapy (CBT) is the most
widely validated treatment for depression. Recent reviews show
positive impacts of face-to-face CBT on depressive symptoms,
quality of life, fasting glucose levels [12], and self-care [13] in
people with T2DM. However, the majority of people with
T2DM are cared for in the primary care setting, and depression
screening in primary care is highly variable. Within a
standard-length consultation, it is difficult for general
practitioners to focus on mental health as well as glycemic
control and prevention of diabetes complications; in addition,
many patients are reluctant to accept a referral for face-to-face
psychotherapeutic interventions [14]. Concerns about
confidentiality, stigma, treatment cost, and time and lifestyle
constraints are further barriers to patients’ help seeking, and
psychological services are often scarce in rural and remote areas.
In addition, the sizeable base rates of comorbid T2DM and
depressive symptoms [15] mean that improved screening and
diagnosis will likely place further pressure on face-to-face
psychological services, many of which already struggle to meet
the needs of their community [16,17]. Therefore, testing more
flexible and scalable models of mental health service delivery
for people with T2DM is necessary [12].
Internet delivery of evidence-based psychological therapies is
now established as apopular, clinically effective, and
cost-efficient means of upscaling access to psychological
treatments. In people with T2DM, both diabetes-specific [18,19]
and generic (ie, not diabetes sensitive but with therapist
guidance) [20] depression interventions have yielded positive
treatment effects for both depression symptoms and
diabetes-related distress. There is also some suggestion that
these may provide a potentially cost-effective solution to the
substantial disability resulting from depression-diabetes
comorbidity [21]. The current literature suggests that such
interventions are most effective for people experiencing
mild-to-moderate depressive symptoms [22]. As subclinical
depression is more prevalent in T2DM than severe depression
[23,24], testing of low-intensity Web-based interventions in
T2DM patients with mild-to-moderate depressive symptoms is
a public health priority.
myCompass is a broadly available Web-based CBT program
available free of charge in Australia. A previous trial reported
symptom reduction of mild-to-moderate depression in the
general population compared with a placebo condition [25].
Despite being self-guided and transdiagnostic (ie, not diabetes
specific) in therapeutic content, an uncontrolled feasibility study
suggested that myCompass may potentially improve functional
and mental health outcomes in people with diabetes [26]. As
such, it may provide a more flexible, scalable alternative to
disease-specific interventions and may benefit people with
T2DM whose depressive symptoms do not warrant more
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intensive face-to-face intervention and/or who wish to manage
their mental health themselves.
Objectives
The primary aim of this randomized controlled trial (RCT) was
to evaluate the effectiveness of myCompass in improving work
and social functioning—a major contributor to the T2DM
burdens [8]—in adults with T2DM and mild-to-moderate
depressive symptoms. On the basis of our feasibility data, we
hypothesized that participants using the myCompass intervention
would show improved scores on a self-report measure of work
and social functioning relative to participants using an active
placebo program. The secondary aim was to determine the
effectiveness of myCompass for improving a range of
diabetes-specific outcomes linked with depression and also
shown to impact health outcomes in T2DM, including
diabetes-related distress, diabetes self-care, and anxiety
symptoms. The inclusion of these variables enabled us to
examine whether treatment of depression with a public health
intervention was capable of impacting diabetes-specific
outcomes.
Methods
Design
This study is the primary outcomes evaluation of a 2-arm RCT
called SpringboarD. The full protocol for the SpringboarD Trial
is published elsewhere [27]. In the full SpringboarD trial,
outcomes will be assessed at baseline and 3, 6, and 12 months
postrandomization. This paper reports data from baseline and
3 months postintervention. Participants in the active and control
groups had uninterrupted access to usual treatment for their
diabetes throughout the study. This study was approved by
Human Research Ethics Committee (HREC) at University of
New South Wales (UNSW) Sydney (HREC 15090) and
registered with the Australia and New Zealand Clinical Trials
Registry (ACTRN12615000931572).
Participants and Setting
The study utilized a broadly-based recruitment strategy,
including offline and online recruitment methods, to enroll the
required sample size for sufficient statistical power. Recruitment
began in September 2015 and continued until November 2017.
Offline recruitment occurred via letters from participating
general practices in New South Wales (NSW) and Victoria to
their patients with T2DM, distribution of promotional materials
in general practice settings throughout NSW and Victoria (eg,
study flyers and posters), and print advertisements in national
diabetes-related publications.
Online recruitment involved a range of techniques targeting
health professionals and individuals. Health professionals were
targeted through member associations such as the Australian
Association of Practice Managers, the Australian Diabetes
Educators Association, the Australian Association of Practice
Nurses and the Australian Primary Health Care Nurses
Association. Contact was via electronic direct mail, informing
members of the study and inviting them to refer appropriate
candidates to the SpringboarD website for screening.
Individuals were recruited via Google and Facebook
advertisements targeting an Australia-wide audience aged 18
years and over, with interest in diabetes mellitus type 2
awareness, diabetes type 2 awareness and/or diabetes
awareness. Advertisements provided a click-through link to a
dedicated page on Black Dog Institute’s website from which
the SpringboarD website could be accessed for information and
screening. Potential candidates were also contacted via email
through Black Dog Institute’s Volunteer Research Register
(VRR) and the Sax Institute’s 45 and Up Study. The VRR
distributed 2378 emails to research volunteers aged between 18
and 75 years with a history of depressive symptoms. The 45
and Up Study is a large, longitudinal population-based cohort
study of healthy aging in NSW, Australia, described in detail
elsewhere [28]. The 267,153 study participants are considered
largely representative of the Australian population. From June
2017 to September 2017, 4175 participants from the 45 and Up
Study aged between 45 and 75 years with self-reported diabetes
were emailed invitations to participate in the SpringboarD study.
All promotional material directed potential candidates to a
secure study-specific website [29], which guided interested
participants through the consent process and provided
instructions regarding completion of the screening
questionnaires.
Eligibility Criteria
People were eligible to take part if they were aged 18 to 75
years, diagnosed with T2DM by a physician, screened positive
for depression on the self-report 2-item Patient Health
Questionnaire (PHQ-2; ie, ≥2) [30], and had access to an
internet-enabled device (eg, computer, tablet, and/or mobile
phone). People who screened positive for depression completed
the 9-item PHQ (PHQ-9) [31] at screening so that the level of
symptom severity could be determined. Exclusion criteria
included insufficient English literacy, extremely severe
depressive symptoms on the full PHQ-9 (score >19), probable
psychosis (measured by the psychosis screener developed for
the Australian National Mental Health and Wellbeing Survey)
[32], currently receiving face-to-face counseling or therapy for
depression, change in antidepressant medication within the
previous 2 months, high suicide risk (assessed by the PHQ-9
Item-9), and previous use of the myCompass program.
Eligible participants received immediate feedback of their
suitability for the study via the website and were provided
onscreen instructions for completion of the baseline assessment.
Approximately 25 min were required to complete the screening
and baseline assessment. All data captured by the study website
during the screening, baseline, and postintervention assessments
were stored in password-protected files on secure servers that
comply with UNSW HREC privacy regulations regarding online
data collection.
Randomization
Computerized block randomization with blocks of 8 was
undertaken to assign participants to the intervention and control
condition at a 1:1 allocation ratio. Randomization was initiated
immediately after the completion of the baseline assessment by
the automated randomization system built into Black Dog
Institute’s study management software. Allocation was
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concealed from participants and researchers. Though participants
were ineligible if they had previously used myCompass, some
participants allocated to the intervention condition may have
independently accessed public information about myCompass
over the course of the trial and therefore become aware that
they were allocated to an existing Web-based therapy program.
Interventions
Active Intervention (myCompass)
myCompass (mycompass.org.au) is a public health fully
automated, self-guided CBT intervention that users complete
in their own time and at their own pace on their computer and/or
mobile phone (see Figures 1 and 2).
Figure 1. Screenshot of the myCompass landing page.
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Figure 2. Screenshot of the myCompass self-monitoring page.
The program offers a personalized treatment plan based on an
assessment of user symptoms, either at registration or at any
time during program use [25,27]. The core program consists of
12 interactive CBT modules and 20 cognitive and/or behavioral
variables for self-monitoring. For maximum outcomes, users
are recommended to complete 3 modules and 3 self-monitoring
variables. The myCompass program offers flexibility for users
to select their own CBT modules and self-monitoring variables,
or, if they prefer, algorithm-based guidance. It provides access
to a range of other resources including short message service
(SMS) text messaging and/or email self-monitoring reminders,
home practice activities to facilitate skill generalization, mental
health care tips and motivational statements delivered by
email/SMS text messaging, and graphical reporting of
self-monitoring data. Registering to use myCompass is free,
and users are not billed for the SMSs they receive.
Participants randomized to the myCompass arm were provided
access to the full program for 8 weeks. The program
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recommended that users complete 3 CBT modules and
self-monitor up to 3 symptoms or behaviors. A 4-week
tailing-off period followed, in which only the symptom
monitoring function was accessible. Studies have shown that
the use of Web-based interventions is improved when users
receive program feedback that is personalized in its content
[33]. For this reason, myCompass users receive automated and
personalized feedback via email about their use of the program’s
self-monitoring and module functions in weeks 1, 3, 5, and 7.
myCompass user privacy is managed by a password-protected
log-on and by ensuring that user-generated data (eg,
self-monitoring ratings) are not stored on the user’s device but
are instead transferred via the internet using secure sockets layer
protocols (which encrypt transmitted data by rendering data
unreadable to anyone other than the intended recipient) and by
storing the data in secure servers. Participant user data were
identified in myCompass using email details provided during
study registration. Once extracted, data were deidentified and
stored in a password-protected file.
Placebo Intervention (Healthy Lifestyles)
The placebo control program, Healthy Lifestyles, was adapted
from a control program used in previous studies by members
of the research team [34] to replicate the mode of delivery and
key functionality of myCompass, but without the therapeutic
content. The program contains 12 modules that deliver health
and lifestyle information across a range of topics (eg, skin care
and mobile phone hygiene), interactive exercises, and the
potential for program tailoring via a brief survey completed at
registration. Program users received an email at weeks 1, 3, 5,
and 7, containing a brief reminder to log into the program but
no feedback about their program use. They also received a
weekly SMS text message containing a fact relevant to the
content of Healthy Lifestyles for the first 4 weeks of the
intervention period to match the SMS functionality of
myCompass. The Healthy Lifestyles program was designed to
have high face validity as a health and lifestyle intervention
without any symptomatic benefit [34]. Participants had full
access to the Healthy Lifestyles program for 8 weeks. The core
features of each program are presented in Table 1.
Outcome Measures
A summary of the measures obtained from participants at
baseline and 3 months postintervention is presented in Table 2.
Table 1. A comparison of the core features of the myCompass and Healthy Lifestyles programs.
Healthy LifestylesMyCompassFeature
WebsiteWebsiteModality
Not availableYes: track up to 3 symptomsSymptom tracking
Yes: automated emailYes: automated short message service text message or emailUsage reminders
12: including interactive learning activities12: including interactive learning activitiesNumber of modules
Generic health literacy informationCognitive and behavioral strategies for mood, anxiety, stress, and mental
well-being
Module content
Table 2. Measures obtained at each assessment phase.
Time 2Time 1Measure
Demographic and disease-related information
—
aXDemographic data (eg, age and gender)
XXDisease-relevant data (eg, age at diagnosis and treatment)
—XMental health history (eg, previous diagnoses and help-seeking)
Primary outcome
XXWork and Social Adjustment Scale [31]
Secondary outcome
XXPatient Health Questionnaire-9 [26] 
XXDiabetes Distress Scale [33] 
XXGeneralized Anxiety Disorder Scale [34] 
XXSelf-management Profile for Type 2 Diabetes Scale (behavior items only) [35] 
—XGlycosylated hemoglobin 
XXDays out of role [36] 
XXHealth service utilization 
aNot applicable.
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Primary Outcome
The primary outcome for the trial was a between-group
difference in work and social functioning, measured by the
Work and Social Adjustment Scale (WSAS). The WSAS is a
psychometrically sound measure of daily functioning across 5
domains, including work, social leisure activities, private leisure
activities, home management, and personal relationships [35,36].
Scores range from 0 to 40, with higher scores indicating poorer
functioning.
Secondary Outcomes
Symptoms of depression and anxiety were measured by PHQ-9
[31] and the 7-item Generalized Anxiety Disorder scale
(GAD-7) [37], respectively. Both scales are well validated, are
used widely as screening tools in primary care settings and are
frequently included as outcome measures in studies of
Web-based interventions [38,39]. Both scales use cut-off scores
of 5, 10, and 15 to identify people with mild, moderate, and
moderately severe symptoms, respectively.
Emotional adjustment to diabetes—or diabetes-related distress
—was measured by the 17-item Diabetes Distress Scale (DDS)
[40]. The DDS yields a total score plus 4 subscale scores
assessing the perceived emotional burden of diabetes, along
with physician-related distress, regimen-related distress, and
interpersonal distress. DDS total and subscale scores are
calculated as the average across all items in the scale/subscale
and range from 1 to 6, with higher scores indicating greater
distress. A score of >3 indicates clinically relevant distress.
Diabetes self-care was assessed using a subset of items from
the Self-Management Profile for Type 2 Diabetes (SMP-T2D).
The SMP-T2D was designed for use in clinical trials to assess
level and perceived ease of performance of specific T2DM
regimen behaviors. Perceived coping and confidence dealing
with diabetes and ease of weight management are also assessed,
and all constructs demonstrate appropriate internal consistency,
validity, and sensitivity [41]. To avoid redundancy (eg, the DDS
also asks about difficulties with self-care activities), to reduce
participant assessment burden, and as we were primarily
interested in learning about participants’ behavioral engagement
in self-care activities, we only administered items that measured
the level of self-care across 4 patient behavior domains: blood
glucose monitoring, medication adherence, healthy eating, and
physical activity. Scores in each behavior domain are converted
to a percentage of the previous week spent engaging in a
particular self-care behavior. Higher scores indicate greater time
spent on self-care [41].
Additional Measurements
At baseline, we collected disease-related (eg, age of onset and
treatment regimen), sociodemographic (eg, age, gender,
education, and occupation) and mental health history data (eg,
service use and previous diagnoses). We also obtained
participants’ most recent glycosylated hemoglobin (HbA1c)
from their medical records as an indicator of their overall blood
glucose management before study commencement. Recent
service utilization for physical and mental health problems was
assessed at baseline and postintervention, along with days out
of role, defined as the number of days in the previous 30 days
that a participant was unable to perform work or normal
activities because of problems with his/her physical or mental
health [42].
At the conclusion of the intervention period, program
engagement data were extracted for myCompass and Healthy
Lifestyles, including frequency of log-in, number of modules
started and completed, and self-monitoring frequency
(myCompass only).
Sample Size
Power calculations indicated that a study sample of 600 was
needed to detect a minimum difference of .3 standard deviations
between groups in mean change in scores on the WSAS at 3
months post intervention, with power of 80%, 2-tailed
alpha=.05, and assuming an attrition rate of 40%. Owing to
early indications of a higher attrition rate at postintervention
than anticipated, a further 180 people were recruited into the
study to ensure sufficient power to test the research hypotheses.
Analyses
Primary analyses employed an intention-to-treat (ITT) approach
using mixed-model repeated measures analyses (MMRM)
computed within the Mixed procedure of SPSS version 23 (IBM
Corp.). MMRM makes use of all available data to obtain
parameter estimates and is widely recognized as an appropriate
strategy for analyzing incomplete datasets [43]. In this study,
restricted maximum likelihood estimation was employed to
estimate model parameters, and error degrees of freedom were
calculated using Satterthwaite approximation. In line with
Fairclough and Helms’ [44] recommendation that the covariance
structure be restricted in situations of high attrition, analyses
assumed a compound symmetric structure. Repeated measures
(Level 1) were nested within individuals (Level 2), and a random
intercept was used at the individual level to account for
intraindividual correlations on repeated measures.
In addition to the ITT analyses, we conducted completer
analyses to examine the effects of treatment on those individuals
who completed the study, defined as having provided complete
data at 3-month follow-up. In these analyses, individuals with
any missing data at 3-month follow-up were deleted case wise
(myCompass n=175; Healthy Lifestyles n=151), and
repeated-measures analyses of variance were conducted for
each of the primary and secondary outcomes on the remaining
participants. As the sample characteristics and treatment effects
in the completer analyses did not differ from those of the ITT
analyses, only the ITT results are reported.
Results
Sample Characteristics
Overall sample characteristics are presented in Table 3, and
participant flow through the study is presented in Figure 3. Of
the 6145 visits to the SpringboarD Project website, 3223
consented to Web-based screening, yielding 888 eligible
participants who commenced the baseline assessment. The main
reasons for ineligibility included the following: did not meet
inclusion criteria for the presence of depressive symptoms, that
is, a score of <2 on the PHQ-2 (52.07% [1021/1961]), currently
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receiving face-to-face mental health support (26.31%
[516/1961]), and screening results indicating severe depression
(9.33% [183/1961]). A total of 780 individuals completed the
baseline assessment and were randomized. A total of 57 people
subsequently withdrew study consent, leaving a final study
sample of 723 individuals.
As shown in Table 3, groups were well matched between the
trial arms. The myCompass group reported stable antidepressant
use of somewhat longer duration than the Healthy Lifestyles
group, with no other notable differences in demographics and
mental health. The overall sample was predominantly female
(68.8% [498/723]), married (55.7% [408/723]), employed at
least part time (50.8% [367/723]), university educated (34.02%
[246/723]), with an average age of 58 years (SD 10.35). More
than 3 quarters of the sample (83.9% [607/723]) had at some
time sought professional help for common mental health issues
(eg, low mood, anxiety and/or stress), and almost half (43.8%
[317/723]) had previously received at least one mental health
diagnosis, the most frequent being depression (40.9%
[296/723]).
Table 3. Sample characteristics for myCompass and Healthy Lifestyles groups.
Healthy Lifestyles (N=355)myCompass (N=368)Characteristic
Demographics
57.7 (10.0)57.7 (10.6)Age, mean (SD) 
236 (66)229 (62)Female (n=465), n (%) 
183 (52)204 (55)Married (n=387), n (%) 
178 (50)173 (47)Employed (n=351), n (%) 
Education level, n (%) 
108 (30)112 (30)Secondary school or lower (n=220)  
137 (39)133 (36)Trade certificate or diploma (n=270)  
110 (31)123 (33)University undergraduate or more (n=233)  
Mental health
Lifetime history, n (%) 
275 (77)296 (80)Sought professional support for mental health (n=571)  
145 (41)155 (42)Received mental health diagnosis (n=300)  
136 (38)143 (38)Diagnosed with depressive symptoms or major depressive disorder (n=279)  
Past 6 weeks, n (%) 
48 (14)65 (18)Sought professional support for mental health (n=113)  
Current, n (%) 
116 (33)125 (34)Taking antidepressant medication (n=241)  
73.67 (56.21)a97.70 (94.72)Months using antidepressant medication  
Diabetes
47.2 (10.9)46.6 (11.1)Age at diagnosis, mean (SD) 
Diabetes treatment, n (%) 
207 (58)a230 (63)Healthy eating (n=437)  
147 (41)176 (48)Physical activity (n=323)  
288 (81)295 (80)Oral medication (n=583)  
103 (29)113 (31)Insulin (n=216)  
11 (3)21 (6)Exenatide (n=32)  
Past 6 weeks, n (%) 
201 (57)218 (59)Visited general practitioner for diabetes (n=419)  
1.37 (.71)1.31 (.78)Frequency of general practitioner visit  
11 (3)13 (4)Hospitalized for diabetes (n=24)  
1.36 (.9)1.46 (1.5)Frequency of hospitalization for diabetes 
aMeans differ significantly at P<.05.
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Figure 3. Consolidated Standards for Reporting of Trials diagram of participant flow through the SpringboarD trial. PHQ: Patient Health Questionnaire.
Diabetes-related characteristics were also largely similar
between the groups. The average age of onset of T2DM for the
sample was 47 years (SD 10.84), and for the 60.0% (434/723)
of participants for whom HbA1c data were available from
medical records, the mean value was 7.5% (SD 1.6).
Baseline scores for key outcome measures for both groups are
presented in Table 4. Again, randomization was largely
successful, with 2 exceptions noted for the WSAS (F1, 782=5.807;
P=.02; d=0.17) and SMP-T2D Healthy Eating Domain (F1,
782=15.925; P=.03; d=0.29). However, when the relevant
normative cut-offs were applied, baseline scores on the key
outcome variables were near to the normal range. WSAS scores
were at the lower end of the significant impairment range of 10
to 20 [35] (sample mean 12.89), PHQ-9 scores were slightly
above the most common diagnostic cut-off of 10 [31] (sample
mean 11.06), scores on the DDS were below the recommended
clinical cut-off of ≥3 [40] (sample mean 2.54), and scores on
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the GAD-7 were also below the recommended clinical cut-off
of ≥3 [37] (sample mean 7.45).
Intention-to-Treat Analyses (Mixed-Model Repeated
Measures Analyses)
The observed scores for all study outcomes postintervention
are presented in Table 4, and the group and time fixed effects
from the MMRM analyses are shown in Table 5. Irrespective
of the intervention received, all participants reported a
significant reduction in WSAS scores across time. Similarly,
all participants showed symptomatic improvements on the
PHQ-9, DDS, and GAD-7 between baseline and
postintervention, with no between-group differences detected
posttreatment on any of these measures. The average mean
reductions across time were generally small and did not meet
any recommended threshold for clinical significance.
For the SMP-T2D, no group or time differences were observed
for the Physical Activity Domain, and both groups reported
significant improvement in the Healthy Eating Domain. Scores
on the Blood Glucose Monitoring Domain and Medication
Adherence Domain increased over time for the Healthy
Lifestyles group relative to the myCompass group, with Healthy
Lifestyles participants increasing time spent each week
monitoring blood glucose and taking medication as
recommended by approximately .4 to .5 days, compared with
their myCompass counterparts.
Posthoc Treatment Effect Moderation Analyses
Level of glycemic control [45] and severity of depression
symptoms [46] are potential moderators of treatment effects,
and age remained a consistent predictor of overall symptomatic
improvement in our sample. We therefore examined the possible
moderating role of these variables by repeating our MMRM
approach with an additional 3-way interaction term that included
the moderator variable of interest (ie, Group×Time×Moderator).
Depressive symptoms were dichotomized into “clinical” and
“subclinical” groups on the basis of the PHQ-9 diagnostic cut-off
of 12 recommended for individuals with diabetes [31]. Level
of glycemic control was determined using conventional HbA1c
targets for T2DM, with >7% indicative of suboptimal control
and ≤7% indicative of well-controlled diabetes [47]. Age was
grouped using a median split. No moderator demonstrated a
significant impact on treatment effects (all P>.05).
Table 4. Baseline and postintervention means (SDs) on key outcome variables for myCompass and Healthy Lifestyles groups.
Post (3 months), mean (SD)Baseline, mean (SD)Measure
Healthy Lifestyles (n=241)myCompass (n=232)Healthy Lifestyles (n=387)myCompass (n=397)
10.82 (9.19)12.24 (9.31)12.23b (7.77)13.64b (7.93)WSASa
8.24 (5.54)8.68 (5.63)10.86 (4.11)11.30 (4.03)PHQ-9c
6.20 (4.58)6.66 (4.73)7.33 (4.20)7.60 (4.10)GAD-7d
2.18 (0.95)2.24 (0.99)2.56 (0.95)2.56 (0.97)DDSe
55.83 (40.21)49.25 (39.33)45.55 (38.85)49.61 (39.50)SMP-BGf
92.04 (15.12)86.34 (24.15)87.20 (22.82)87.50 (22.47)SMP-MAg
54.87 (28.25)53.52 (28.94)48.26b (28.61)49.96b (29.16)SMP-HEh
52.44 (34.07)55.98 (34.64)48.26 (33.61)53.44 (33.48)SMP-PAi
bMeans differ significantly at P<.05.
aWSAS: Work and Social Adjustment Scale.
cPHQ-9: Patient Health Questionnaire.
dGAD-7: Generalized Anxiety Disorder Scale.
eDDS: Diabetes Distress Scale.
fSMP-BG: Self-Management Profile for Type 2 Diabetes—Blood Glucose Monitoring.
gSMP-MA: Self-Management Profile for Type 2 Diabetes—Medication Adherence.
hSMP-HE: Self-Management Profile for Type 2 Diabetes—Healthy Eating.
iSMP-PA: Self-Management Profile for Type 2 Diabetes—Physical Activity.
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Table 5. Mixed-model repeated measures analyses fixed effects for time, group, and time×group on key outcome variables.
95% CIP valuet test (df)SEBetaaVariable and effect
WSASb
0.401 to 2.287
.005c2.800 (544.48)0.481.344Time
–1.147 to 1.540.770.287 (550.76)0.6840.196Group×Time
PHQ-9d
1.787 to 3.003<.001c7.736 (596.32)0.312.395Time
–0.720 to 1.008.740.326 (604.61)0.440.144Group×Time
DDSe
0.208 to 0.395<.001c6.361 (518.94)0.0470.302Time
–0.194 to 0.070.36–0.919 (523.64)0.068–0.062Group×Time
GAD-7f
0.490 to 1.526<.001c3.825 (553.83)0.2641.009Time
–1.013 to 0.460.46–0.736 (560.75)0.375–0.276Group×Time
SMP-BGg
–12.727 to –3.778<.001c–3.623 (538.46)2.278–8.253Time
2.598 to 15.360
.006c2.764 (545.46)3.2488.98Group×Time
SMP-MAh
–5.562 to –0.688
.01c–2.520 (490.84)1.24–3.126Time
1.651 to 8.582
.004c2.901 (496.65)1.7635.117Group×Time
SMP-HEi
–8.856 to –2.550<.001c–3.553 (527.04)1.604–5.704Time
–1.217 to 7.750.151.430 (532.61)2.2823.266Group×Time
SMP-PAj
–7.816 to 0.936.12–1.543 (559)2.228–3.440Time
–6.301 to 6.134.980.541 (566.75)3.1650.083Group×Time
aBeta: unstandardized regression coefficient for the effect holding constant age and sex.
bWSAS: Work and Social Adjustment Scale.
cSignificant at P<.05.
dPHQ-9: Patient Health Questionnaire-9 item.
eDDS: Diabetes Distress Scale.
fGAD-7: Generalized Anxiety Disorder Scale-7 item.
gSMP-BG: Self-Management Profile for Type 2 Diabetes—Blood Glucose Monitoring.
hSMP-MA: Self-Management Profile for Type 2 Diabetes—Medication Adherence.
iSMP-HE: Self-Management Profile for Type 2 Diabetes—Healthy Eating.
jSMP-PA: Self-Management Profile for Type 2 Diabetes—Physical Activity.
Study Attrition
Of the total trial participants, 59.2% (235/397) of the participants
from the myCompass program and 63.3% (245/387) of the
participants from the Healthy Lifestyles program provided at
least one postintervention measure. A multivariate analysis of
variance comparing nonresponders (ie, participants who did not
provide any postintervention measures) with responders at
baseline revealed differences on several key outcome variables.
Nonresponders reported more severe depressive symptoms
(F=8.362; P=.004; d=0.27), more severe anxiety symptoms
(F=3.845; P=.05; d=0.18), greater diabetes-related distress
(F=9.095; P=.003; d=0.28) and poorer medication adherence
(F=6.564; P=.011; d=0.19). In a follow-up logistic regression
predicting responder status from baseline WSAS, PHQ-9,
GAD-7, DDS, and SMP-T2D scores, PHQ-9 (beta=–.058;
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P=.021; OR [odds ratio] .943; 95% CI [.898, .991]), DDS
(beta=–.221; P=.026; OR 1.029; 95% CI [.660, .974]) and
WSAS (beta=.029; P=.016; OR .802; 95% CI [1.005, 1.054])
scores independently predicted nonresponse. Though effects
were generally small, it appears that levels of distress and
functioning had some influence on participants remaining in
the study.
Program Use and Feedback
Participants in the treatment group logged in to myCompass an
average of 6 times (SD 9.01; range 1-71), started a mean of 0.71
modules (SD 1.18; range 0 to 8), fully completed an average of
.29 modules (SD .87; range 0-7), and monitored their symptoms
an average of 2 times (SD 5.79; range 0-53). Participants in the
control group logged in to Healthy Lifestyles an average of 4
times (SD 3.22; range 1 to 17), started a mean of 2.61 (SD 2.78;
range 0 to 8), and completed an average of 1.37 modules (SD
2.24; range 0 to 8). Participants who logged in to their assigned
Web-based program did not differ significantly from those who
did not, except for a slightly higher anxiety score on the GAD-7
among myCompass users who logged in (F=10.76; P=.001;
d=0.39). Adherence indices did not correlate with baseline
scores on any primary or secondary outcome. Approximately
54.7% (127/232) of myCompass participants and 11.2%
(27/241) of Healthy Lifestyles participants reported that, overall,
they found their assigned Web-based program both easy and
convenient to use.
Discussion
Principal Findings
This trial examined the effectiveness of a self-help, unguided
Web-based CBT program (myCompass) for improving work
and social functioning in people with T2DM and
mild-to-moderate depressive symptoms compared with an active
placebo intervention. Our ITT analyses showed that participants’
work and social functioning improved significantly
postintervention, irrespective of the intervention received.
Significant improvements were also observed for both groups
in depressive and anxiety symptoms, diabetes distress, and most
aspects of diabetes self-management. Our Healthy Lifestyles
group showed small but significant improvements in blood
glucose monitoring and medication adherence over and above
those observed for the myCompass group. As morbidity may
influence the outcomes of depression treatments [46] and as
age remained a significant outcome predictor in our models,
we examined the potential moderator effects on treatment
outcomes of age, depressive symptoms, and diabetes control.
Analyses revealed that treatment effect estimates were not
impacted by these variables.
The absence of differential treatment effects for work and social
functioning and depressive symptoms for people with T2DM
following treatment with myCompass was surprising in light
of previous findings of accelerated symptom gains in
myCompass users in the general community [27] and in our
pilot study [26]. Although our findings also contrast with
previous studies of Web-based depression interventions in
people with diabetes [18,20], there are important points of
differentiation between this study and previous diabetes trials
that need to be considered in interpreting our findings.
Our recruitment methods targeted people with T2DM and
mild-to-moderate depressive symptoms to investigate a public
health rather than a clinical application of Web-based CBT;
however, our final sample unexpectedly comprised a group with
minimal symptoms of depression (47% of participants in the
minimal-to-mild range on the PHQ-9). This contrasts with
previous studies of people with diabetes that included only
patients with more severe depressive symptoms [18] or those
meeting criteria for major depressive disorder (Newby et al,
2017). Moreover, although 58% of our participants reported
impaired work and social functioning at baseline, scores on the
WSAS suggested that the level of impairment experienced by
our participant group was again at the milder end of the
disability spectrum. In other words, by all measures, our sample
was only minimally impaired at baseline.
Even in the absence of true depression, people with chronic
illness typically report poorer daily functioning than those
without [48]. Consequently, our statistical analyses were based
on a participant group with baseline scores on the WSAS and
PHQ-9 that were potentially at floor for this cohort, and
therefore, any improvement was likely to be minor. Also
contrasting with previous studies [20], we observed a systematic
pattern of attrition, such that increased severity of depressive
symptoms was linked to study dropout. Systematic attrition of
those in greatest need of intervention, and for whom treatment
benefits were likely to be largest, may have further magnified
any floor effects in our study [49] and precluded us from finding
larger and more significant functional and symptom
improvements following treatment with myCompass.
It is important to understand why and how increasing severity
of depressive symptoms compromises study involvement in
trials of Web-based CBT to inform the take-up of suitable
interventions for this patient cohort and to maximize treatment
effectiveness. One possibility is that attrition is related to
increasing levels of amotivation, concentration difficulties, and
behavioral inactivation that are hallmark symptoms of depressive
disorders [50]. Alternatively, anhedonia (ie, reduced capacity
to experience and anticipate enjoyment from activities) has been
shown to compromise reward-seeking behavior and decision
making [51] and might interfere with program uptake by
rendering user behavior less responsive to reinforcement history
(eg, motivational feedback) and anticipatory benefits (eg,
information about program effectiveness) [52]. An accumulating
body of evidence suggests that analysis of individual or clusters
of depression symptoms may be necessary for understanding
behavioral health outcomes in diabetes patients [53,54]. More
precise understanding of relationships between depressive
symptoms and indicators of program uptake and treatment
benefit in T2DM is a challenge for future research.
Importantly, the myCompass program is a completely
self-guided mental health intervention that is generic in content.
It is, therefore, lower in treatment intensity than previously
studied therapist-guided programs [20], and it lacks the disease
specificity of diabetes-themed programs [18,19]. Fisher and
colleagues [24] have previously suggested that scores on
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depression screeners may be less reflective of mood disturbance
than general emotional and diabetes-specific distress, that is,
distress experienced in response to the daily challenges and
demands of living with diabetes. In line with this, we have
recently published data showing that mildly depressed adults
with diabetes maintain a very nuanced conceptualization of their
mental health symptoms in which low mood, anxiety, and stress
are generally perceived as features of the diabetes diagnosis
(and warranted by contextual stressors) and not separate or
comorbid conditions to be managed [55]. Lack of differentiation
of mild-to-moderate depression symptoms from adjustment to
diabetes has potential to attenuate the personal relevance and
clinical effectiveness of interventions targeting broad CBT skills
and techniques. At the same time, mild-to-moderate depression
covers different levels of symptom severity that may differ in
terms of responsiveness to internet-based CBT. Further
exploration of the conceptualization of depression in T2DM
and associated implications for depression treatment is
warranted. Moreover, we recommend that researchers examine
the nature of comorbidity between depression and
diabetes-related distress. If discrete patterns of depressive
symptoms and diabetes-related distress can be distinguished,
then different interventions (eg, therapist guided versus
unguided, generic versus diabetes specific) may be needed to
maximize symptom improvement and increase social and
occupational functioning in each.
Of the set of secondary outcomes, the only consistent group
effect was for medication adherence, with a small but significant
positive effect for the attention control. This finding was isolated
and seemingly counterintuitive. However, it is possible that
improvement in medication taking was prompted by the focus
paid by the attention control program to healthy lifestyle
behaviors.
Strengths and Limitations
Recruitment and retention in RCTs targeting comorbid physical
and mental illness can be difficult [56]. Despite a lengthy and
comprehensive community recruitment strategy, and our
adoption of retention strategies that have been used successfully
in other studies, participant enrollment and retention for our
trial was challenging (and will be discussed in a future
publication). Although we were successful in retaining a sample
that afforded us sufficient power to test our research hypotheses,
attrition in our study was systematic. As a result, near-normal
scores on baseline variables may have influenced program
engagement (that was generally low) and weakened tests of
treatment effects. Moreover, our data are mostly relevant to
people with T2DM experiencing mild functional impairment
and mild depressive symptoms. Future studies may benefit from
broadening eligibility symptom thresholds. Moreover, research
designs that include greater program guidance and feedback
(eg, module recommendations and homework follow-up) and
provide more regular research support (eg, reminders and
encouragement) may be more acceptable to participants with
higher levels of impairment, for whom motivational factors are
likely to impact ongoing study involvement. Importantly,
recruitment and retention in future trials may benefit from
further investigation of factors influencing individuals’ decisions
to decline trial participation or drop out post study
commencement.
Although previous trials of Web-based CBT in people with
diabetes have compared the active treatment with either
treatment as usual [20] or waitlist control [18], a key strength
of our design was the inclusion of an attention-placebo condition
using a health literacy tool that had been validated elsewhere
[25,34]. However, it is possible that lifestyle information had
unexpected relevance to our chronically ill cohort, who were
mostly experiencing only minor psychological distress. This
may have resulted in increased engagement with the Healthy
Lifestyles program and afforded benefit to our control condition
in addition to the intended placebo effect. Further assessment
with a waitlist and/or treatment-as-usual control group is
required.
Conclusions
In conclusion, this study sought to determine if a broadly
available public health Web-based CBT intervention could help
individuals with T2DM and mild-to-moderate depressive
symptoms improve their daily lives. Functioning and symptom
outcomes improved between baseline and postintervention;
however, no treatment advantage was observed for the
myCompass group. Further research is necessary to identify the
factors that impact participant retention in studies of Web-based
interventions in T2DM, especially among those in greatest need
of psychological support and who stand to benefit most from
treatment. At the same time, there is a need to better understand
how individuals with diabetes conceptualize mood symptoms
in the context of diabetes to ensure that Web-based interventions
are both personally and clinically relevant. The personal and
societal health burdens posed by comorbid T2DM and
depressive symptoms are considerable and will continue to
grow. Continued investigation of the potential for Web-based
CBT to provide a solution in T2DM is essential.
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